利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.027 秒)

    CL-1577 Antibiotic compounds and their production
    2.
    发明授权
    CL-1577 Antibiotic compounds and their production 失效
    CL-1577抗生素化合物及其生产

    公开(公告)号：US4530835A

    公开(公告)日：1985-07-23

    申请号：US512088

    申请日：1983-07-08

    申请人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Tim A. Smitka ,  Josefino B. Tunac

    发明人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Tim A. Smitka ,  Josefino B. Tunac

    IPC分类号： A61K35/74 ,  A61P31/04 ,  A61P35/00 ,  C07G11/00 ,  C12N1/20 ,  C12P1/06 ,  C12R1/465

    CPC分类号： C12P1/06

    摘要： A purified isolate of an actinomycete identified as ATCC 39363 is capable of producing a complex of sulfur-containing antibiotic compounds having activity against transplanted tumors.Antibiotic compounds CL-1577A and CL-1577B and their closely related congeners are produced by cultivating isolate ATCC 39363 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1577 complex is produced, and subsequently isolating the complex or one or more of the compounds.The antibiotic compounds CL-1577A, CL-1577B, their congeners, and pharmaceutical compositions comprising these substances together with a suitable carrier are also disclosed.

    摘要翻译： 确定为ATCC 39363的放线菌的纯化分离物能够产生具有针对移植肿瘤的活性的含硫抗生素化合物的复合物。 抗生素化合物CL-1577A和CL-1577B及其密切相关的同系物通过在需氧条件下培养分离物ATCC 39363，在含有可同化碳源和氮的来源的培养基中培养，直到产生大量的CL-1577复合物，随后 分离复合物或一种或多种化合物。 还公开了抗生素化合物CL-1577A，CL-1577B，它们的同系物和包含这些物质的药物组合物和合适的载体。

    CL-1957E antibiotic compound and its production
    3.
    发明授权
    CL-1957E antibiotic compound and its production 失效
    CL-1957E抗生素化合物及其生产

    公开(公告)号：US4725621A

    公开(公告)日：1988-02-16

    申请号：US835825

    申请日：1986-03-03

    申请人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Neil E. Willmer

    发明人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Neil E. Willmer

    IPC分类号： C07D309/30 ,  A61K31/365

    CPC分类号： C07D309/30

    摘要： A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957E which also exhibits antitumor properties.The antimicrobial compound CL-1957E is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantially quantity of the CL-1957E compound is produced, and subsequently isolating the CL-1957E compound.The antibiotic compound CL-1957E and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

    摘要翻译： 确定为ATCC 39366的放线菌的纯化分离物能够生产也具有抗肿瘤性质的抗微生物化合物CL-1957E。 抗微生物化合物CL-1957E是通过在需氧条件下培养含有可同化碳源和氮源的培养基中分离的ATCC 39366产生的，直到产生大量的CL-1957E化合物，然后分离出CL-1957E化合物。 还公开了抗生素化合物CL-1957E和包含该物质的药物组合物与药学上可接受的载体，以及使用这些药物组合物治疗哺乳动物的微生物感染和肿瘤的方法。

    CL-1957D antibiotic compound and its production
    4.
    发明授权
    CL-1957D antibiotic compound and its production 失效
    CL-1957D抗生素复方及其生产

    公开(公告)号：US4696794A

    公开(公告)日：1987-09-29

    申请号：US928443

    申请日：1986-11-07

    申请人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Neil E. Willmer

    发明人： Richard H. Bunge ,  James C. French ,  Timothy R. Hurley ,  Neil E. Willmer

    IPC分类号： C12P1/06 ,  A61K35/74 ,  C12D1/06

    CPC分类号： C12P1/06

    摘要： A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957D.The antimicrobial compound CL-1957D is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957D compound is produced, and subsequently isolating the CL-1957D compound.The antibiotic compound CL-1957D and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections in mammals, employing these pharmaceutical compositions.

    摘要翻译： 确定为ATCC 39366的放线菌的纯化分离物能够产生抗微生物化合物CL-1957D。 抗微生物化合物CL-1957D是通过在需氧条件下培养含有可同化碳源和氮源的培养基中分离的ATCC 39366产生的，直到产生大量的CL-1957D化合物，然后分离出CL-1957D化合物。 还公开了抗生素化合物CL-1957D和包含该物质的药物组合物与药学上可接受的载体，以及使用这些药物组合物治疗哺乳动物微生物感染的方法。

    CL-1577-B.sub.4 compound, its production and use
    10.
    发明授权
    CL-1577-B.sub.4 compound, its production and use 失效
    CL-1577-B4化合物，其生产和使用

    公开(公告)号：US4661353A

    公开(公告)日：1987-04-28

    申请号：US804411

    申请日：1985-12-04

    申请人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    发明人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    IPC分类号： C07G11/00 ,  A61K35/74 ,  A61P31/04 ,  A61P35/00 ,  C12N1/20 ,  C12P1/06 ,  C12R1/01 ,  C12R1/04

    CPC分类号： C12P1/06

    摘要： CL-1577-B.sub.4 compound is derived by the solvolysis under anhydrous conditions of either CL-1577A compound of CL-1577B compound, obtained from the fermentative action of a purified strain of Actinomycete designated ATCC 39363 under aerobic conditions.CL-1577-B.sub.4 compound is a potent antimicrobial agent, possessing activity against a number of gram-positive and gram-negative bacteria, yeasts, and fungi. In addition, the compound exhibits in vivo activity against the P388 murine leukemia cell line and in vitro activity against the L1210 murine leukemia cell line.A method of making the compound as well as pharmaceutical compositions and methods for their use are also disclosed.

    摘要翻译： CL-1577-B4化合物是通过在无氧条件下溶解分解得到的CL-1577B化合物的CL-1577B化合物，其由在有氧条件下命名为ATCC 39363的纯化的放线菌菌株的发酵作用获得。 CL-1577-B4化合物是一种有效的抗微生物剂，具有抗多种革兰氏阳性和革兰氏阴性细菌，酵母菌和真菌的活性。 此外，该化合物对P388鼠白血病细胞系具有体内活性，对L1210鼠白血病细胞系具有体外活性。 还公开了制备该化合物的方法以及其使用的药物组合物和方法。